Table 3A Dose 1 pharmacokinetic parameters of plasma β-lapachone following intravenous administration of ARQ 761

From: Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis

Dose (mg/m2)

Infusion time

N

AUC(0–last) (ng × h/mL)

Cmax (ng/mL)

Half-life (h)a

195

1 h

4

10,463 ± 6103

1294 ± 258

1.8 ± 1.0

195

2 h

3

23,369 ± 15,1287

947 ± 233

3.1 ± 2.0

390

1 h

4

23,910 ± 20,745

2418 ± 705

1.2 ± 0.9

390

2 h

13

33,150 ± 27,468

1798 ± 738

2.6 ± 1.5

450

2 h

10

21,276 ± 13,323

1652 ± 442

1.5 ± 1.4

  1. aHalf-life of elimination from the central compartment of the two-compartment model
Back to article page